Immune checkpoint inhibitors, including Bristol-Myers Squibb’s Opdivo, Merck & Co.’s Keytruda, and Roche’s Tecentriq, are revolutionizing the therapeutic strategies for several cancers. This…
Recent European approval of three anti-CGRP-targeted MAbs—Aimovig (Novartis), Ajovy (Teva) and Emgality (Eli Lilly)—together with the expected market penetration of the fourth anti-CGRP-…
MARKET OUTLOOK Type 2 diabetes (T2D) has an extremely high prevalence in the top five European markets (France, Germany, Italy, Spain, UK). Low-cost metformin (Merck KgaA’s Glucophage, generics)…
MARKET OUTLOOK The treatment landscape for psoriasis in the top 5 European markets (France, Germany, Italy, Spain, UK) is extremely dynamic. Humira (AbbVie), Enbrel (Amgen), Stelara (Janssen), and…
MARKET OUTLOOK The European atopic dermatitis (AD) market has entered a new era. In 2017, IL-4/13 inhibitor Dupixent (Sanofi/Regeneron) became the first targeted biologic to be approved for…
DRG Epidemiology’s coverage of neuroendocrine tumor comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of…
Methicillin-Resistant Staphylococcus aureus EpidemiologyDRG Epidemiology’s coverage of methicillin-resistant staphylococcus aureus comprises epidemiological estimates of key patient populations…
Clarivate Epidemiology’s coverage of hospital treated (HT) gram-positive infections (GPIs) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the…
Clarivate Epidemiology’s coverage of dyslipidemia comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of dyslipidemia for each…